Publications in collaboration with researchers from University of California, San Francisco (37)

2023

  1. Holistic Treatment Response: An International Expert Panel Definition and Criteria for a New Paradigm in the Assessment of Clinical Outcomes of Spinal Cord Stimulation

    Neuromodulation, Vol. 26, Núm. 5, pp. 1015-1022

  2. Impact of Long-Term Evoked Compound Action Potential Controlled Closed-Loop Spinal Cord Stimulation on Sleep Quality in Patients With Chronic Pain: An EVOKE Randomized Controlled Trial Study Subanalysis

    Neuromodulation, Vol. 26, Núm. 5, pp. 1030-1038

  3. XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

    Breast Cancer Research, Vol. 25, Núm. 1

2022

  1. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

    Life science alliance, Vol. 5, Núm. 4

  2. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

    JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052

  3. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 10, Núm. 4, pp. 367-377

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism

    American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150

  3. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained

    Journal of Bone and Mineral Research, Vol. 36, Núm. 2, pp. 236-243

2020

  1. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

  2. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

    Breast Cancer Research and Treatment, Vol. 184, Núm. 1, pp. 161-172

  3. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials

    The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 8, pp. 672-682

2019

  1. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

    Future Oncology, Vol. 15, Núm. 19, pp. 2211-2225

  2. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research, Vol. 34, Núm. 4, pp. 632-642

  3. Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita

    Human Mutation, Vol. 40, Núm. 12, pp. 2270-2285

  4. Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research

2018

  1. Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol

    Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357

  2. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course 06 Biological Sciences 0604 Genetics 11 Medical and Health Sciences 1109 Neurosciences

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication

    Heart Rhythm, Vol. 14, Núm. 1, pp. e3-e40

  2. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7)

    Breast Cancer Research and Treatment